Bedrijfsoverzicht
VYNE Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for chronic inflammatory and immune-mediated conditions. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which focuses on the discovery and commercialization of innovative medical treatments. As of the latest available data, the company maintains a market capitalization of $20.33M and employs 10 individuals to advance its research pipeline. The annual revenue recorded over the trailing twelve months is $570,000, a figure that reflects the early-stage nature of the business where revenue generation is currently limited. These valuation metrics indicate that VYNE is a small-cap company with limited commercial traction, relying heavily on its lead program, repibresib gel (VYN201), to transition from clinical development to market entry. The low revenue base combined with a market cap under $25 million suggests the firm is in a capital-intensive phase of development where success depends on clinical trial outcomes rather than current sales performance.
Financiële gezondheid
The company reported a revenue of $570,000 for the trailing twelve months, while the net income stood at -$26,736,000 and EBITDA was -$29,726,000. The substantial disparity between the minimal revenue and the significant negative net income highlights a cost structure dominated by research, development, and operational expenses typical of clinical-stage biotechnology firms. Free cash flow amounted to -$26,668,124, indicating a heavy cash burn rate that limits immediate financial flexibility but is a common characteristic for companies in the drug discovery phase. The gross margin is listed at 100.0%, which is standard for companies with negligible cost of goods sold in the pre-commercialization stage, whereas the operating margin of -4014.6% and profit margin of 0.0% underscore the extensive overhead costs required to sustain clinical trials. Regarding liquidity, the company holds $29.01M in cash and maintains a debt position of $0, resulting in a debt-to-equity ratio that is effectively N/A due to the lack of equity or debt data in standard reporting contexts. This balance sheet structure is highly conservative regarding leverage, as the firm carries no debt obligations to service interest payments. Furthermore, a current ratio of 12.53 demonstrates robust short-term liquidity, providing ample resources to cover liabilities with existing cash reserves. However, the return on equity is -67.0% and the return on assets is -38.3%, metrics that reveal management is currently generating losses across the balance sheet rather than positive returns on deployed capital.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is reported as -0.37, a metric that reflects the inability to value the stock based on traditional earnings multiples at this stage. The price-to-book ratio stands at 0.73, suggesting the market is currently pricing the company at a discount relative to its book value, though this metric holds limited interpretive value for a pre-revenue biotechnology firm. Alternative valuation metrics such as the price-to-sales ratio of 35.66 and an EV/EBITDA of 0.29 provide context for investors, indicating a high multiple relative to sales given the tiny revenue base and near-zero enterprise value earnings. The stock has traded within a 52-week range with a high of $1.99 and a low of $0.28, placing the current valuation context within this broad historical band. The beta value of 1.95 indicates that the stock exhibits high volatility, moving significantly more than the broader market index in response to general market fluctuations. This elevated beta is characteristic of small-cap biotechnology stocks where price movements are often driven by specific clinical data releases rather than macroeconomic factors.
Growth & Income
Revenue growth year-over-year is recorded at 54.8%, whereas earnings growth is N/A due to the company's ongoing losses, implying that top-line expansion is occurring before profitability is achieved. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a capital allocation strategy where all available cash is reinvested into research and development rather than distributed to shareholders. This reinvestment approach is necessary for a clinical-stage company to fund its pipeline and reach commercial milestones before generating positive cash flows. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash burn and no current income generation for investors.